20 results about "Dextran 40" patented technology

The invention discloses a cell freezing medium and application thereof, and belongs to the technical field of biology, the cell freezing medium comprises the following components: 5-10% of DMSO, 50-75% of dextran 40 glucose injection, 15-45% of human serum albumin, 2.5-5% of compound electrolyte solution, 5-20% of hydroxyethyl starch electrolyte injection, 10-40ng / mL of vitamin C, and 10-40ng / mL of vitamin B6.

The invention belongs to the field of cell preparations, and relates to a mesenchymal stem cell intravenous injection for osteoporosis diseases, the injection comprises an injection, MSC and endothelial progenitor cells, the MSC and the endothelial progenitor cells are obtained by co-separation culture from umbilical cord tissues; wherein the content of MSC cells is not less than 90%, and the content of endothelial progenitor cells is not more than 10%; the injection comprises normal saline, a compound electrolyte injection, a dextran 40 glucose injection or a hyaluronic acid injection. The preparation containing the MSC cells is simple and clear in component, free of toxic and side effects and good in stability.

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to an ambroxol hydrochloride-containing oral liquid and application thereof, and the ambroxol hydrochloride oral liquid is composed of ambroxol hydrochloride, ligustrazine, meglumine, dextran 40, xylitol, carboxymethylcellulose, L-tryptophan, stevioside and purified water. The ligustrazine and the ambroxol hydrochloride play a synergistic effect, and the meglumine and the dextran 40 are combined for use, so that the stability of the ambroxol hydrochloride is improved. Accelerated experiments show that the ambroxol hydrochloride is stable in property and suitable for further industrial mass production.

The application discloses an intelligent antibacterial hydrogel combined with a photosensitizer and an antibiotic as well as a preparation method and application thereof. The hydrogel takes oxidized dextran 40 as a hydrogel matrix, bonds 5-amino hexyl acetylpropionate into OAHAL through a Schiff base reaction, and is then crosslinked with amikacin to be prepared. The hydrogel has pH sensitivity, can effectively release drugs under an inflammatory slightly acidic environment, realizes on-demand release of the drugs, avoids overuse of the antibiotic, reduces toxic side effects, simultaneously loads two kinds of bactericidal drugs, 5-amino hexyl acetylpropionate and amikacin, and synergistically resists bacteria through two different mechanisms of photodynamic therapy and antibiotics, so that the antibacterial effect is significantly improved, and bacterial colonies caused by various types of wounds can be eliminated, and bacterial infection of a wound surface can be effectively prevented or treated.

This invention belongs to the technical field of cell preservation, specifically relating to a clinical cryopreservation solution for canine natural killer cells, its preparation method, and its application. The invention uses physiological saline as a solvent and dextran 40, a complex amino acid, canine serum albumin, canine interleukin-2, and sodium bisulfite as active ingredients. The complex amino acid includes three or more of leucine, isoleucine, phenylalanine, threonine, tryptophan, methionine, glycine, lysine hydrochloride, arginine, histidine, and valine. The cell cryopreservation solution provided by this invention is free of serum and DMSO, has a stable and safe composition, and the components work synergistically to provide a stable survival environment for canine natural killer cells. After preservation at 4℃~8℃ for 72 hours, the viability of canine natural killer cells can be maintained at over 80%, achieving in vitro preservation of canine natural killer cells while retaining good killing activity against canine mammary tumor cells.

The invention relates to a CAR-NK (chimeric antigen receptor-natural killer) cell cryopreservation solution for clinical use as well as a preparation method and application thereof. The CAR-NK cell freezing medium disclosed by the invention is prepared from a washing solution, a dextran 40 glucose injection and Cryostat CS10, or is prepared from the washing solution, human serum albumin and Cryostat CS10; wherein the washing liquid is prepared from sodium chloride injection and human serum albumin. The cryopreservation liquid disclosed by the invention is used for cryopreserving CAR-NK cells, does not have the problem of cell agglomeration, and can effectively maintain the viability and vitality of the cells; the cryopreservation liquid is simple in component, is in a GMP level or a medicine level, can be directly infused back to a human body, is convenient to prepare and easy to prepare in a large scale, and saves the production and manufacturing cost.

The invention relates to a freezing medium and a freezing method for universal CAR (chimeric antigen receptor) cells. The cryopreservation liquid comprises a compound electrolyte injection, a human serum albumin injection, a sodium chloride injection, a dextran 40 glucose injection, a glucose injection, dimethyl sulfoxide and trehalose. The cell cryopreservation process is deeply analyzed, the specific cell cryopreservation liquid and the cryopreservation method are designed, all the components of the cryopreservation liquid are synergistic, the cryopreservation liquid can adapt to the specific cooling process, cell damage in the cryopreservation process is effectively reduced, the activity of the cryopreserved cells is effectively kept, the cryopreservation liquid can be directly used for reinfusion of patients, a specific sectional programmed cooling program is adopted, and the cell cryopreservation process is simplified. The cell cryopreservation device can further adapt to different cryopreservation volumes, so that the cryopreservation effect is further improved, the survival rate of cells is effectively guaranteed, and the cryopreserved cells still keep good cell activity.

The present invention relates to a special cryopreservation solution for hepatocytes and a preparation method therefor, and belongs to the technical field of cell cryopreservation and thawing. The special cryopreservation solution for hepatocytes comprises the following components: a cryoprotectant, a biofilm protectant and an antioxidant. The biofilm protectant comprises an inhibitor Y27632, glycerol, human serum albumin, collagen and a dextran 40 sodium chloride injection. The special cryopreservation solution for hepatocytes of the present invention can effectively improve the hydrophobicity of the biofilm and reduce the fluidity of the biofilm, so that the damage to the biofilm of hepatocytes caused by ice crystals during the freezing and thawing processes is minimized, and the cell viability of hepatocytes after thawing is significantly improved.

The invention relates to the technical field of epidemic disease detection of aquatic animals, in particular to a composite freeze-drying protective agent for a giant salamander iridovirus detection reagent and a preparation method of the reagent. The composite freeze-drying protective agent is mainly prepared from the following components: trehalose, glucan and hydroxyethyl starch according to the mass ratio of (3 to 5) to (0.8 to 1.2) to (0.3 to 0.7). The three-component composite protective agent is adopted, trehalose, dextran 40 and hydroxyethyl starch are mixed for use, protein is effectively protected, the glass transition temperature is prevented from being too high or too low, and redissolution and caking are inhibited. In the freeze-drying process of the detection reagent based on the protective agent, Q92R / E118K double mutation is performed on Taq enzyme, so that a dual protection mechanism for freeze-drying damage is formed; stepwise heating is introduced in the sublimation stage, and the freeze-drying time is shortened to 12 h; the detection reagent is treated through the gradient annealing freeze-drying process, so that the enzyme retention rate can reach 95% or above. The zero turbidity (OD600 is less than 0.05) of the redissolved reagent is ensured, and the interference of fluorescence detection is eliminated.

The present invention belongs to the technical field of drug analysis, and specifically relates to a method and application for determining the ribose content in transfer factor for injection. The determination method comprises the following steps: (1) preparation of a test solution: weighing sterile powder of transfer factor for injection, dissolving it in water, then adding solution A for dilution, centrifuging, taking the supernatant to evaporate, adding trichloroacetic acid solution to dissolve, and obtaining a test solution; (2) preparation of a reference solution; (3) determination: taking the test solution, and determining the absorbance at 645-655nm using the orcinol colorimetric method; (4) drawing a standard curve; (5) calculation of the ribose content; wherein the solution A described in step (1) is a mixed solution of methanol, ethanol and acetonitrile. The present invention eliminates the interference problem of dextran 40 in the determination of ribose in transfer factor for injection by optimizing the sample pretreatment process, thereby improving the accuracy of the determination method.

Described herein are DMSO formulations and methods for cell therapy. Methods of treating a cell with these formulations are also provided. The embodiments provide a formulation that maintains the suspension and viability of a T-cell during cell therapy (CT) manufacturing and through a cryopreservation thaw cycle, including dimethyl sulfoxide (DMSO); sucrose or trehalose; human semm albumin (HSA); and dextran 40 or hydroxyethyl starch (HES). wherein the formulation maintains the suspension and viability of T-cells during CT manufacturing and through a cryopreservation thaw cycle. The embodiments provide a method for maintaining a suspension and cell viability, including subjecting a T-cell during a cell therapy manufacturing cryopreservation thaw cycle to a formulation including DMSO; sucrose or trehalose; human semm albumin (HSA); and polysaccharide or HES wherein the formulation maintains the suspension and viability of a T-cell during cell therapy manufacturing and through a cryopreservation thaw cycle.

This invention provides an endothelial glycocalyx-protective perfusion solution composition, kit, and application for isolated lung perfusion. The composition comprises an organ flushing solution, a basal perfusion solution, and an endothelial glycocalyx protectant. The organ flushing solution includes dextran 40, electrolytes, buffer solutions, anticoagulants, and vasodilators. The basal perfusion solution includes albumin, dextran 40, electrolytes, glucose, buffer salts, anticoagulants, anti-inflammatory agents, anti-infective agents, and vasodilators. This invention uses the basal perfusion solution as the main component, adding an endothelial glycocalyx protectant to form a composite perfusion system. This system is used to inhibit or reduce the degradation and shedding of pulmonary vascular endothelial glycocalyx, maintain structural stability, reduce the risk of perfusion-related pulmonary edema and inflammatory damage, thereby improving the maintenance effect of isolated lung function. The product can be designed as a kit.

The invention provides a stable defibrase preparation. The defibrase preparation consists of defibrase, dextran 40, trehalose and a solvent for injection. The invention also provides a preparation method and a quality control method of the injection, the preparation is simple in prescription, the prepared freeze-dried preparation is better in stability during storage and convenient to use, and compared with the injection prepared from defibrase, the stability is better.

The present invention provides a mesenchymal stem cell drug formulation and its preparation process, belonging to the field of biomedical technology. The mesenchymal stem cell drug formulation combination provided by the present invention includes a mesenchymal stem cell solution and a self-assembly solution; the mesenchymal stem cell solution is composed of mesenchymal stem cells, human serum albumin, heparin, dextran 40, and a compound electrolyte solution, and the self-assembly solution is composed of protamine, dipotassium glycyrrhizinate, rosmarinic acid, and physiological saline. The mesenchymal stem cell drug formulation combination provided by the present invention can improve the cell activity and stability of mesenchymal stem cells, highly express CD73, CD90, CD105, HGF, and sTNFR1, and has a good immune regulation function, providing a new idea for the clinical application of mesenchymal stem cells.

The invention belongs to the technical field of biological medicine, and particularly relates to a construction method and application of an in-situ liver cancer animal model. The construction method comprises the following steps: inoculating human hepatoma carcinoma cells into a culture medium for culture, digesting with pancreatin, centrifuging, and discarding supernatant to obtain a cell suspension; and injecting the cell suspension into the animal liver in a targeted manner to obtain the in-situ liver cancer animal model. The culture medium comprises the following components: a basic culture medium, fetal calf serum, hepatocyte growth factors, rat tail collagen, beta-mercaptoethanol, dextran 40, a ROCK inhibitor, insulin, non-essential amino acids and antibiotics. Compared with a method for constructing the in-situ liver cancer animal model in the prior art, the method has the advantages that the required tumor cell inoculation amount is small, the modeling period is obviously shortened, the modeling success rate is improved, and scientific guidance is provided for exploring the pathogenesis of liver cancer and formulating the standardized production process of liver cancer model animals.

The invention relates to the technical field of medicines, in particular to an L-4-boryl phenylalanine intravenous injection as well as a preparation method and application thereof. According to the L-4-boryl phenylalanine intravenous injection disclosed by the invention, a glucose-low molecular dextran complexing agent (in a mass ratio of (3-5): 1) or a maltitol-polyethylene glycol 400 complexing agent (in a mass ratio of (2-4): 1) is used as a solubilizer to replace saccharides such as D-sorbitol, fructose and the like used in the prior art. The composite solubilizer provided by the invention not only can significantly improve the solubility of L-BPA, but also can enhance the stability of a preparation, and realizes room temperature preservation. According to the preparation method, an integrated process of ultrasonic-assisted dissolution, buffer pair adjustment and nanofiltration infiltration reduction is adopted, a traditional sodium hydroxide-hydrochloric acid adjustment system is avoided, the pH value is accurately controlled through a citric acid-sodium dihydrogen phosphate buffer pair, excessive ions are removed in cooperation with a nanofiltration technology, and a salt-free preparation process is achieved.

The invention relates to a preserving fluid for prolonging the low-temperature preservation time of NK cells as well as a preparation method and application of the preserving fluid. The preserving fluid is prepared from the following components: dextran 40 glucose injection, 10% glucose injection, 50% glucose injection, 20% human serum albumin, compound amino acid injection, trehalose, coenzyme Q10, phellinus igniarius and normal saline. The compound amino acid injection is supplemented with three specific active substances including the trehalose, the coenzyme Q10 and the phellinus linteus, and compared with other carbohydrates, the trehalose can achieve an obviously excellent NK cell low-temperature preservation effect; wherein the coenzyme Q10 and the phellinus linteus play a role through anti-oxidation and anti-apoptosis characteristics, can maintain the metabolic activity of the NK cells and reduce oxidative damage, and have an obvious synergistic promotion effect in the aspect of improving the low-temperature preservation effect of the NK cells. The components in the preserving fluid are mutually formulated, so that an excellent NK cell low-temperature preserving effect is integrally realized.

The invention relates to the technical field of immune cells, and discloses a high-activity immune cell cryopreservation method and a high-activity immune cell recovery method. The cryopreservation protective agent is prepared from the following raw materials in percentage by volume: 8 to 12 percent of dimethyl sulfoxide, 5 to 8 percent of trehalose, 5 to 10 percent of dextran 40 to 60, 2 to 4 percent of human serum albumin, 0.1 to 0.5 percent of a cell factor mixture, 3 to 6 percent of an active protective agent and the balance of a basic culture medium. According to the invention, trehalose, dextran 40-60 and an active protective agent composed of a mitochondrial targeting antioxidant SS-31, a caspase inhibitor Z-VAD-FMK and membrane stability polypeptide are introduced, and the concentration and addition mode of dimethyl sulfoxide are strictly controlled, so that the damage of a traditional cryopreservation protective agent to cells due to osmotic pressure impact and chemical toxicity can be reduced.

The invention provides a nasal-absorbed stem cell exosome preparation and a preparation method thereof, the nasal-absorbed stem cell exosome preparation comprises an exosome and a matrix solution, and the matrix solution comprises 0.9% of sodium chloride injection, 5-10% of human serum albumin, 10-20% of dextran 40 glucose injection, 20-30% of glycerin fructose sodium chloride injection, 20-50 [mu] g / ml of ganglioside sodium and 4-8 [mu] g / ml of edaravone injection. The stem cell exosome preparation prepared from the stem cell exosome and the matrix solution can be preserved at-20 DEG C for 12 months, and can be preserved at 2-8 DEG C for 15 days after thawing, the number of the exosomes, surface protein expression and the form of vesicles can be well maintained, and the stem cell exosome preparation is clear and safe in component. Exosome administration is carried out through nasal mucosa to enter brain tissue parts, endogenous neural stem cells of organisms are activated and nourished, a regeneration microenvironment is established, nerve injury repair is promoted, and the exosome is used for preventing, treating and improving cognitive impairment and traumatic brain injury of senile dementia. The preparation is simple and convenient to prepare, small in toxic and side effects and convenient to dose.

The present invention relates to a preservation solution for extending the low-temperature preservation time of NK cells, a preparation method thereof, and an application thereof. The components of the preservation solution include: dextran 40 glucose injection, 10% glucose injection, 50% glucose injection, 20% human serum albumin, compound amino acid injection, trehalose, coenzyme Q10, mulberry flavonoids, and normal saline. The present invention uses compound amino acid injection supplemented with three specific active substances, trehalose, coenzyme Q10, and mulberry flavonoids, wherein trehalose can achieve significantly excellent NK cell low-temperature preservation effects compared with other sugar substances; wherein coenzyme Q10 and mulberry flavonoids play a role through antioxidant and anti-apoptotic properties, can maintain the metabolic activity of NK cells and reduce oxidative damage, and the two have a significant synergistic promoting effect in improving the low-temperature preservation effect of NK cells. The components in the preservation solution of the present invention are mutually formulated to achieve an excellent NK cell low-temperature preservation effect as a whole.